EpiSignaLR: an open resource for genome-wide episignature analysis from methylation-aware short- and long-read sequencing
- 1Department of Genome Sciences, University of Washington
Abstract
BackgroundEpisignatures, disorder-specific patterns of genome-wide DNA methylation, are established for more than 100 Mendelian conditions and help resolve variants of uncertain significance and evaluate unsolved cases. Current clinical testing approaches typically use data generated by methylation arrays, which require a specific assay and limit discovery to the probe set of the array. Long-read and Illumina 5-base genome sequencing measure CpG methylation alongside genetic variation, raising the possibility of folding episignature analysis into a single genome-wide test.
MethodsWe sequenced individuals with SETD1B-related neurodevelopmental disorder, Kabuki syndrome, or Kleefstra syndrome, along with controls, using Oxford Nanopore Technologies (ONT), PacBio HiFi, or Illumina 5-base whole-genome sequencing. We identified differentially methylated regions (DMRs) directly from ONT methylation data and built classifiers using a nested cross-validation framework.
ResultsWe identified 143 DMRs for SETD1B-related neurodevelopmental disorder (SETD1B-NDD), 20 for Kabuki syndrome, and 23 for Kleefstra syndrome; 15 to 26% of the DMRs across the three signatures contained no array probe(s). Cross-validated classifiers ranked every case above every control for all three conditions, and the final classifiers called all but one held-out case correctly, with the remaining case, which carries a KMT2D missense variant, as indeterminate. At two outside sites, the classifier for SETD1B-NDD correctly categorized seven out of seven cases. Principal component analysis reveals most PacBio and Illumina 5-base genomes cluster with ONT genomes from the same condition. One PacBio control fell between the other controls and the Kabuki cases, whereas the ONT and 5-base genomes for the same individual grouped with controls, suggesting platform-specific methylation differences that the current training cohort is too small to fully account for.
ConclusionsEpisignatures can be derived directly from sequencing data and applied across platforms. EpiSignaLR is an open workflow that combines the three ONT-derived classifiers with 34 published array-derived signatures. Developing robust sequencing-derived episignatures will require larger cohorts per condition and openly shared, platform-matched methylation data.
Related
- Towards Democratizing CNS Tumor Classification: 10-fold reduction in methylation sequencing cost with the Flongle Flow Cell
- Rapid whole-genome sequencing in the pediatric intensive care unit: from etiologic diagnosis to precision management—a narrative review
- Genome-wide cell-free DNA methylation profiling via TAPS for moyamoya disease diagnosis and postoperative collateral formation prediction
- Proximity-mapped whole-genome sequencing for characterization of repeat expansions and variants in highly homologous genomic regions
- Juvenile Huntington Disease With Cerebellar‐Predominant Atrophy Identified by Genome Sequencing
BibTeX
@misc{gibson2026episignalr,
title = {{EpiSignaLR: an open resource for genome-wide episignature analysis from methylation-aware short- and long-read sequencing}},
author = {S. B. Gibson and M. P. G. Zalusky and J. Goffena and E. J. Hamlin and R. Lamb and J. R. Rosinski and T. Prall and Z. B. Anderson and S. H. R. Storz and A. L. Miller and Y. Shi and K. Lanko and D. Mulder and Y. Shen and K. Lensing and M. G. Elferink and S. Vergano and M. H. Wojcik and K. L. I. van Gassen and W. T. Gibson and S. J. M. Jones and T. S. Barakat and D. E. Miller},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.21.26366070},
url = {https://www.medrxiv.org/content/10.64898/2026.10.21.26366070v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - EpiSignaLR: an open resource for genome-wide episignature analysis from methylation-aware short- and long-read sequencing
AU - S. B. Gibson
AU - M. P. G. Zalusky
AU - J. Goffena
AU - E. J. Hamlin
AU - R. Lamb
AU - J. R. Rosinski
AU - T. Prall
AU - Z. B. Anderson
AU - S. H. R. Storz
AU - A. L. Miller
AU - Y. Shi
AU - K. Lanko
AU - D. Mulder
AU - Y. Shen
AU - K. Lensing
AU - M. G. Elferink
AU - S. Vergano
AU - M. H. Wojcik
AU - K. L. I. van Gassen
AU - W. T. Gibson
AU - S. J. M. Jones
AU - T. S. Barakat
AU - D. E. Miller
PY - 2026
DA - 2026/10/21
PB - medRxiv
DO - 10.64898/2026.10.21.26366070
UR - https://www.medrxiv.org/content/10.64898/2026.10.21.26366070v1
AB - BackgroundEpisignatures, disorder-specific patterns of genome-wide DNA methylation, are established for more than 100 Mendelian conditions and help resolve variants of uncertain significance and evaluate unsolved cases. Current clinical testing approaches typically use data generated by methylation arrays, which require a specific assay and limit discovery to the probe set of the array. Long-read and Illumina 5-base genome sequencing measure CpG methylation alongside genetic variation, raising the possibility of folding episignature analysis into a single genome-wide test. MethodsWe sequenced individuals with SETD1B-related neurodevelopmental disorder, Kabuki syndrome, or Kleefstra syndrome, along with controls, using Oxford Nanopore Technologies (ONT), PacBio HiFi, or Illumina 5-base whole-genome sequencing. We identified differentially methylated regions (DMRs) directly from ONT methylation data and built classifiers using a nested cross-validation framework. ResultsWe identified 143 DMRs for SETD1B-related neurodevelopmental disorder (SETD1B-NDD), 20 for Kabuki syndrome, and 23 for Kleefstra syndrome; 15 to 26% of the DMRs across the three signatures contained no array probe(s). Cross-validated classifiers ranked every case above every control for all three conditions, and the final classifiers called all but one held-out case correctly, with the remaining case, which carries a KMT2D missense variant, as indeterminate. At two outside sites, the classifier for SETD1B-NDD correctly categorized seven out of seven cases. Principal component analysis reveals most PacBio and Illumina 5-base genomes cluster with ONT genomes from the same condition. One PacBio control fell between the other controls and the Kabuki cases, whereas the ONT and 5-base genomes for the same individual grouped with controls, suggesting platform-specific methylation differences that the current training cohort is too small to fully account for. ConclusionsEpisignatures can be derived directly from sequencing data and applied across platforms. EpiSignaLR is an open workflow that combines the three ONT-derived classifiers with 34 published array-derived signatures. Developing robust sequencing-derived episignatures will require larger cohorts per condition and openly shared, platform-matched methylation data.
ER -